Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Why Regeneron (REGN) is a Top Value Stock for the Long-Term
10:40am, Thursday, 30'th Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Certuity LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
02:45pm, Wednesday, 29'th Apr 2026
Certuity LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 70.7% during the fourth quarter, according to the company in its most recent filing with the Securitie
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript
02:01pm, Wednesday, 29'th Apr 2026
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe
01:57pm, Wednesday, 29'th Apr 2026
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) on Wednesday reported first-quarter adjusted earnings of $9.47 per share, up 15% year-over-year, beating the consensus of $8.89.
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength
01:31pm, Wednesday, 29'th Apr 2026
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
10:30am, Wednesday, 29'th Apr 2026
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength
10:29am, Wednesday, 29'th Apr 2026
A couple of hours ago, Regeneron published its Q1 financial results. So, Eylea HD generated $468 million in U.S. sales for REGN, up 52.4% year-on-year. Moreover, in Q1, Regeneron's revenue from collab
Regeneron shares slide despite Q1 beat
10:13am, Wednesday, 29'th Apr 2026
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares fell more than 5.5% on Wednesday morning even as the drugmaker reported better-than-expected first-quarter results and announced a new share repurcha
Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug
09:10am, Wednesday, 29'th Apr 2026
Regeneron stock fell early Wednesday after U.S. sales of its high-dose Eylea came in below Wall Street's expectations
Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates
08:46am, Wednesday, 29'th Apr 2026
Regeneron (REGN) came out with quarterly earnings of $9.47 per share, beating the Zacks Consensus Estimate of $8.52 per share. This compares to earnings of $8.22 per share a year ago.
Regeneron beats quarterly results estimates on strong Dupixent demand
07:43am, Wednesday, 29'th Apr 2026
Regeneron Pharmaceuticals beat Wall Street estimates for first-quarter profit and revenue on Wednesday, helped by strong demand for its eczema drug, Dupixent, and cancer drug, Libtayo, offsetting c
Regeneron Reports First Quarter 2026 Financial and Operating Results
06:30am, Wednesday, 29'th Apr 2026
TARRYTOWN, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2026 and provided a business update.
Regeneron shares slide despite Q1 beat
06:12am, Wednesday, 29'th Apr 2026
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares fell more than 5.5% on Wednesday morning even as the drugmaker reported better-than-expected...
Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive?
01:15pm, Tuesday, 28'th Apr 2026
Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?
01:11pm, Monday, 27'th Apr 2026
Regeneron eyes Q1 results with Dupixent profits and strong Eylea HD uptake set to offset declining Eylea sales amid rising competition.
